Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023

Table of Contents

1 INTRODUCTION 16

1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 17
1.3.1 MARKET COVERED 17
1.4 YEARS CONSIDERED FOR THE STUDY 18
1.5 CURRENCY 18
1.6 LIMITATIONS 18
1.7 STAKEHOLDERS 18

2 RESEARCH METHODOLOGY 19

2.1 SECONDARY DATA 20
2.1.1 SECONDARY SOURCES 20
2.2 PRIMARY DATA 21
2.2.1 PRIMARY SOURCES 22
2.3 MARKET SIZE ESTIMATION 22
2.3.1 BOTTOM-UP APPROACH 23
2.3.2 TOP-DOWN APPROACH 24
2.4 DATA TRIANGULATION METHODOLOGY 25
2.5 ASSUMPTIONS FOR THE STUDY 26

3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 30

4.1 BIOSIMILARS MARKET OVERVIEW 30
4.2 ASIA: BIOSIMILARS MARKET, BY TYPE OF PRODUCT 31
4.3 BIOSIMILARS MARKET, BY REGION 32
4.4 GEOGRAPHICAL SNAPSHOT: BIOSIMILARS MARKET (MAJOR COUNTRIES) 33

5 MARKET OVERVIEW 34

5.1 INTRODUCTION 34
5.2 MARKET DYNAMICS 34
5.2.1 DRIVERS 35
5.2.1.1 Increasing demand for biosimilar drugs due to their cost-effectiveness 35
5.2.1.2 Rising incidence of chronic diseases 35
5.2.1.3 Strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars 36
5.2.2 RESTRAINTS 37
5.2.2.1 Complexities in manufacturing 37
5.2.2.2 Innovative strategies by biologic drug manufacturers 37
5.2.3 OPPORTUNITIES 38
5.2.3.1 Growth opportunities in emerging markets 38
5.2.3.2 New indications and patent expiry of biologic products 38
5.2.4 CHALLENGES 40
5.2.4.1 Stringent regulatory requirements to adversely affect investments in biosimilars 40

6 REGULATORY OUTLOOK 41

6.1 NORTH AMERICA 41
6.1.1 US 41
6.1.2 CANADA 41
6.2 EUROPE 42
6.3 ASIA PACIFIC 43
6.3.1 CHINA 43
6.3.2 INDIA 43
6.3.3 JAPAN 43
6.3.4 SOUTH KOREA 43
6.4 REST OF THE WORLD 44
6.4.1 BRAZIL 44
6.4.2 MEXICO 44
6.4.3 ARGENTINA 44
6.4.4 SAUDI ARABIA 44

7 BIOSIMILARS MARKET, BY PRODUCT 45

7.1 INTRODUCTION 46
7.2 RECOMBINANT NON-GLYCOSYLATED PROTEINS 47
7.2.1 RECOMBINANT HUMAN GROWTH HORMONE (RHGH) 48
7.2.2 GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM) 49
7.2.3 INSULIN 51
7.2.4 INTERFERONS 52
7.2.4.1 Interferon-beta 53
7.2.4.2 Interferon-alpha 53
7.3 RECOMBINANT GLYCOSYLATED PROTEINS 54
7.3.1 ERYTHROPOIETIN (EPO) 55
7.3.2 MONOCLONAL ANTIBODIES (MABS) 56
7.3.2.1 Infliximab 57
7.3.2.2 Rituximab 58
7.3.2.3 Adalimumab 59
7.3.2.4 Other monoclonal antibodies 61
7.3.3 FOLLITROPIN 62
7.4 RECOMBINANT PEPTIDES 62
7.4.1 GLUCAGON 64
7.4.2 CALCITONIN 64

8 BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING 66

8.1 INTRODUCTION 67
8.2 IN-HOUSE MANUFACTURING 68
8.3 CONTRACT MANUFACTURING 68

9 BIOSIMILARS MARKET, BY DISEASE 70

9.1 INTRODUCTION 71
9.2 ONCOLOGY 72
9.3 CHRONIC DISEASES 73
9.4 AUTOIMMUNE DISEASES 74
9.5 BLOOD DISORDERS 75
9.6 GROWTH HORMONE DEFICIENCY 76
9.7 INFECTIOUS DISEASES 77
9.8 OTHER DISEASES 78

10 BIOSIMILARS MARKET, BY REGION 79

10.1 INTRODUCTION 80
10.2 NORTH AMERICA 81
10.2.1 US 85
10.2.2 CANADA 88
10.3 EUROPE 92
10.3.1 GERMANY 98
10.3.2 FRANCE 100
10.3.3 UK 102
10.3.4 ITALY 104
10.3.5 SPAIN 106
10.3.6 REST OF EUROPE 108
10.4 ASIA 111
10.4.1 INDIA 116
10.4.2 CHINA 121
10.4.3 SOUTH KOREA 124
10.4.4 JAPAN 128
10.4.5 REST OF ASIA 131
10.5 REST OF THE WORLD (ROW) 135
10.5.1 LATIN AMERICA 139
10.5.2 PACIFIC AND OCEANIA 140
10.5.3 MIDDLE EAST AND AFRICA 141

11 COMPETITIVE LANDSCAPE 143

11.1 OVERVIEW 143
11.2 MARKET SHARE ANALYSIS, 2016 144
11.3 COMPETITIVE SCENARIO 145
11.3.1 PRODUCT LAUNCHES AND PRODUCT APPROVALS 145
11.3.2 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS 146
11.3.3 ACQUISITIONS 146
11.3.4 EXPANSIONS 147

12 COMPANY PROFILES 148

(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 SANDOZ 148
12.2 PFIZER 151
12.3 TEVA PAHRMACEUTICAL 154
12.4 CELLTRION 156
12.5 BIOCON 158
12.6 AMGEN 160
12.7 SAMSUNG BIOLOGICS 162
12.8 MYLAN 164
12.9 DR. REDDY'S LABORATORIES 166
12.10 STADA ARZNEIMITTEL AG 168

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX 170

LIST OF TABLES

TABLE 1 MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2015–2018) 36
TABLE 2 LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY 39
TABLE 3 STATUS OF REGULATORY PATHWAY IN NORTH AMERICA 41
TABLE 4 SUBSTITUTION STATUS IN EUROPEAN COUNTRIES 42
TABLE 5 STATUS OF REGULATORY PATHWAY IN ASIA PACIFIC 43
TABLE 6 STATUS OF REGULATORY PATHWAY IN THE ROW 44
TABLE 7 BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 46
TABLE 8 BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 47
TABLE 9 BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS,
BY REGION, 2016–2023 (USD MILLION) 48
TABLE 10 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE,
BY REGION, 2016–2023 (USD MILLION) 49
TABLE 11 LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY-STIMULATING FACTOR PRODUCTS FROM 2013 TO 2016 50
TABLE 12 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR,
BY REGION, 2016–2023 (USD MILLION) 50
TABLE 13 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2016–2023 (USD MILLION) 51
TABLE 14 BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016–2023 (USD MILLION) 52
TABLE 15 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION,
2016–2023 (USD MILLION) 52
TABLE 16 BIOSIMILARS MARKET FOR INTERFERON-BETA , BY REGION,
2016–2023 (USD MILLION) 53
TABLE 17 BIOSIMILARS MARKET FOR INTERFERON-ALPHA, BY REGION,
2016–2023 (USD MILLION) 54
TABLE 18 BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD BILLION) 55
TABLE 19 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN 56
TABLE 20 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION,
2016–2023 (USD MILLION) 56
TABLE 21 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD BILLION) 57
TABLE 22 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY REGION, 2016–2023 (USD MILLION) 57
TABLE 23 PIPELINE OF INFLXIMAB 58
TABLE 24 BIOSIMILARS MARKET FOR INFLXIMAB, BY REGION, 2016–2023 (USD MILLION) 58
TABLE 25 PIPELINE OF RITUXIMAB 59
TABLE 26 BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2016–2023 (USD MILLION) 59
TABLE 27 PIPELINE OF ADLIMUMAB 60
TABLE 28 BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2016–2023 (USD MILLION) 60
TABLE 29 PIPELINE OF OTHER MONOCLONAL ANTIBODIES 61
TABLE 30 BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION,
2016–2023 (USD MILLION) 61
TABLE 31 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2016–2023 (USD MILLION) 62
TABLE 32 BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE,
2016–2023 (USD MILLION) 63
TABLE 33 BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY REGION,
2016–2023 (USD MILLION) 63
TABLE 34 BIOSIMILARS MARKET FOR GLUCAGON, BY REGION, 2016–2023 (USD MILLION) 64
TABLE 35 BIOSIMILARS MARKET FOR CALCITONIN, BY REGION, 2016–2023 (USD MILLION) 65
TABLE 36 BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION) 67
TABLE 37 BIOSIMILARS MARKET FOR IN-HOUSE MANUFACTURING, BY REGION,
2016–2023 (USD BILLION) 68
TABLE 38 BIOSIMILARS MARKET FOR CONTRACT MANUFACTURING, BY REGION,
2016–2023 (USD MILLION) 69
TABLE 39 BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 71
TABLE 40 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2016–2023 (USD MILLION) 72
TABLE 41 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION,
2016–2023 (USD MILLION) 73
TABLE 42 BIOSIMILARS MARKET FOR AUTOIMMUNE DISEASES, BY REGION,
2016–2023 (USD MILLION) 74
TABLE 43 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION,
2016–2023 (USD MILLION) 75
TABLE 44 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY REGION, 2016–2023 (USD MILLION) 76
TABLE 45 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2016–2023 (USD MILLION) 77
TABLE 46 BIOSIMILARS MARKET FOR OTHER DISEASES, BY REGION,
2016–2023 (USD MILLION) 78
TABLE 47 BIOSIMILARS MARKET, BY REGION, 2016–2023 (USD MILLION) 80
TABLE 48 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 82
TABLE 49 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 82
TABLE 50 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 82
TABLE 51 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 83
TABLE 52 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 83
TABLE 53 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 84
TABLE 54 NORTH AMERICA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 84
TABLE 55 NORTH AMERICA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 84
TABLE 56 LIST OF BIOSIMILARS APPROVED IN THE US 85
TABLE 57 US: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 86
TABLE 58 US: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 86
TABLE 59 US: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 86
TABLE 60 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2016–2023 (USD MILLION) 87
TABLE 61 US: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 87
TABLE 62 US: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 88
TABLE 63 LIST OF BIOSIMILARS APPROVED IN CANADA 89
TABLE 64 CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 89
TABLE 65 CANADA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 89
TABLE 66 CANADA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 90
TABLE 67 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 90
TABLE 68 CANADA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 91
TABLE 69 CANADA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 91
TABLE 70 CANADA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 91
TABLE 71 LIST OF BIOSIMILARS APPROVED IN EUROPE 92
TABLE 72 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 95
TABLE 73 EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 95
TABLE 74 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 96
TABLE 75 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 96
TABLE 76 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE,
2016–2023 (USD MILLION) 96
TABLE 77 EUROPE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 97
TABLE 78 EUROPE: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 97
TABLE 79 GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 98
TABLE 80 GERMANY: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 98
TABLE 81 GERMANY: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 99
TABLE 82 GERMANY: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 99
TABLE 83 GERMANY: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 99
TABLE 84 FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 100
TABLE 85 FRANCE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 100
TABLE 86 FRANCE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 101
TABLE 87 FRANCE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 101
TABLE 88 FRANCE: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 101
TABLE 89 LIST OF BIOSIMILARS IN THE UK 102
TABLE 90 UK: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 102
TABLE 91 UK: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 103
TABLE 92 UK: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 103
TABLE 93 UK: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 103
TABLE 94 UK: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 104
TABLE 95 ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 104
TABLE 96 ITALY: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 105
TABLE 97 ITALY: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 105
TABLE 98 ITALY: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 105
TABLE 99 ITALY: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 106
TABLE 100 SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 106
TABLE 101 SPAIN: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 107
TABLE 102 SPAIN: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 107
TABLE 103 SPAIN: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 107
TABLE 104 SPAIN: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 108
TABLE 105 ROE: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 109
TABLE 106 ROE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 109
TABLE 107 ROE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 109
TABLE 108 ROE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 110
TABLE 109 ROE: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 110
TABLE 110 ASIA: BIOSIMILARS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 113
TABLE 111 ASIA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 113
TABLE 112 ASIA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 113
TABLE 113 ASIA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE,
2016–2023 (USD MILLION) 114
TABLE 114 ASIA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 114
TABLE 115 ASIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 114
TABLE 116 ASIA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 115
TABLE 117 ASIA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 115
TABLE 118 ASIA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 115
TABLE 119 BIOLOGICS APPROVED AND MARKETED IN INDIA 116
TABLE 120 INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 118
TABLE 121 INDIA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 119
TABLE 122 INDIA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE,
2016–2023 (USD MILLION) 119
TABLE 123 INDIA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 119
TABLE 124 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 120
TABLE 125 INDIA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 120
TABLE 126 INDIA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 120
TABLE 127 INDIA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 121
TABLE 128 CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 122
TABLE 129 CHINA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 122
TABLE 130 CHINA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE,
2016–2023 (USD MILLION) 122
TABLE 131 CHINA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 123
TABLE 132 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 123
TABLE 133 CHINA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 123
TABLE 134 CHINA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 124
TABLE 135 CHINA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 124
TABLE 136 LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA 125
TABLE 137 SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 125
TABLE 138 SOUTH KOREA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 126
TABLE 139 SOUTH KOREA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 126
TABLE 140 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 127
TABLE 141 SOUTH KOREA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 127
TABLE 142 SOUTH KOREA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 127
TABLE 143 LIST OF BIOSIMILARS APPROVED IN JAPAN 128
TABLE 144 JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 129
TABLE 145 JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 129
TABLE 146 JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 129
TABLE 147 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 130
TABLE 148 JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 130
TABLE 149 JAPAN: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 130
TABLE 150 JAPAN: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 131
TABLE 151 ROA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 132
TABLE 152 ROA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 132
TABLE 153 ROA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE,
2016–2023 (USD MILLION) 132
TABLE 154 ROA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 133
TABLE 155 ROA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 133
TABLE 156 ROA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 133
TABLE 157 ROA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 134
TABLE 158 ROA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 134
TABLE 159 ROW: BIOSIMILARS MARKET, BY REGION, 2016–2023 (USD MILLION) 137
TABLE 160 ROW: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 137
TABLE 161 ROW: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 137
TABLE 162 ROW: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 138
TABLE 163 ROW: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE,
2016–2023 (USD MILLION) 138
TABLE 164 ROW: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 138
TABLE 165 ROW: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 139
TABLE 166 LIST OF SIMILAR BIOTHERAPEUTIC PRODUCTS APPROVED IN LATIN AMERICA 139
TABLE 167 LATIN AMERICA : BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 140
TABLE 168 LIST OF BIOSIMILARS APPROVED IN AUSTRALIA 140
TABLE 169 LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND 141
TABLE 170 PACIFIC AND OCEANIA: BIOSIMILARS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 141
TABLE 171 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 142
TABLE 172 THE COMPANY’S BIOSIMILAR IN PIPELINE ARE LISTED BELOW 152
TABLE 173 THE COMPANY’S BIOSIMILAR IN PIPELINE ARE LISTED BELOW 155
TABLE 174 THE COMPANY’S BIOSIMILAR IN PIPELINE ARE LISTED BELOW 157
TABLE 175 THE COMPANY’S BIOSIMILAR IN PIPELINE ARE LISTED BELOW 161
TABLE 176 THE COMPANY’S BIOSIMILAR IN PIPELINE ARE LISTED BELOW 162

 

LIST OF FIGURES

FIGURE 1 RESEARCH METHODOLOGY 19
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS 21
FIGURE 3 BOTTOM-UP APPROACH 23
FIGURE 4 TOP-DOWN APPROACH 24
FIGURE 5 DATA TRIANGULATION 25
FIGURE 6 BIOSIMILARS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION) 27
FIGURE 7 BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2018 VS. 2023 (USD MILLION) 28
FIGURE 8 BIOSIMILARS MARKET, BY DISEASE, 2018 VS. 2023 (USD MILLION) 28
FIGURE 9 BIOSIMILARS MARKET, BY REGION, 2018 VS. 2023 (USD BILLION) 29
FIGURE 10 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE MARKET 30
FIGURE 11 RECOMBINANT GLYCOSYLATED PROTIENS SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017 31
FIGURE 12 NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE IN 2017 32
FIGURE 13 INDIA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 33
FIGURE 14 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 34
FIGURE 15 INCREASING GERIATRIC POPULATION, BY REGION, 2015 VS. 2030 35
FIGURE 16 GLOBAL INCIDENCE OF DIABETES, BY REGION, 2017 VS. 2045 36
FIGURE 17 BIOSIMILARS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION) 46
FIGURE 18 IN-HOUSE MANUFACTURING SEGMENT TO DOMINATE THE BIOSIMILARS MARKET IN 2018 67
FIGURE 19 ONCOLOGY SEGMENT TO DOMINATE THE BIOSIMILARS MARKET IN 2018 71
FIGURE 20 ASIA TO REGISTER THE HIGHEST GROWTH RATE IN THE BIOSIMILARS MARKET DURING THE FORECAST PERIOD 80
FIGURE 21 NORTH AMERICA: BIOSIMILARS MARKET SNAPSHOT 81
FIGURE 22 CANCER INCIDENCE IN CANADA 88
FIGURE 23 EUROPE: BIOSIMILARS MARKET SNAPSHOT 94
FIGURE 24 ASIA: BIOSIMILARS MARKET SNAPSHOT 112
FIGURE 25 ROW: BIOSIMILARS MARKET SNAPSHOT 136
FIGURE 26 KEY DEVELOPMENTS OF MAJOR PLAYERS FROM 2015 TO 2018 143
FIGURE 27 GLOBAL BIOSIMILARS MARKET SHARE ANALYSIS, BY KEY PLAYER 2016 144
FIGURE 28 SANDOZ: COMPANY SNAPSHOT 148
FIGURE 29 PFIZER: COMPANY SNAPSHOT 151
FIGURE 30 TEVA PHARMACEUTICAL: COMPANY SNAPSHOT 154
FIGURE 31 CELLTRION: COMPANY SNAPSHOT 156
FIGURE 32 BIOCON: COMPANY SNAPSHOT 158
FIGURE 33 AMGEN: COMPANY SNAPSHOT 160
FIGURE 34 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT 162
FIGURE 35 MYLAN: COMPANY SNAPSHOT 164
FIGURE 36 DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT 166
FIGURE 37 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT 168

当レポートのプレスリリースは発行されておりません。